Intensity Therapeutics Inc. (NASDAQ:INTS) Receives $7.00 Average PT from Analysts

Intensity Therapeutics Inc. (NASDAQ:INTS) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $7.00.

A number of equities analysts have commented on the company. HC Wainwright boosted their price objective on Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a report on Tuesday, August 11th. Benchmark reiterated a “speculative buy” rating on shares of Intensity Therapeutics in a research report on Wednesday, May 20th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Tuesday, July 21st.

Intensity Therapeutics Stock Performance

NASDAQ INTS opened at $4.02 on Friday. Intensity Therapeutics has a 1-year low of $3.51 and a 1-year high of $43.50. The company has a 50 day moving average of $4.39 and a 200-day moving average of $4.98. The company has a current ratio of 5.00, a quick ratio of 5.00 and a debt-to-equity ratio of 0.01. The firm has a market cap of $13.13 million, a price-to-earnings ratio of -1.13 and a beta of 2.76.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.24). On average, equities analysts forecast that Intensity Therapeutics will post -2.64 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Intensity Therapeutics

A number of large investors have recently modified their holdings of INTS. Jane Street Group LLC acquired a new stake in shares of Intensity Therapeutics in the fourth quarter valued at approximately $26,000. Corient Private Wealth LLC bought a new position in Intensity Therapeutics in the 4th quarter valued at $41,000. State Street Corp boosted its position in Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after buying an additional 121,700 shares during the last quarter. Mesirow Financial Investment Management Inc. raised its position in shares of Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after acquiring an additional 51,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after acquiring an additional 201,357 shares during the period. 3.74% of the stock is currently owned by institutional investors and hedge funds.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.